Abaxx Calls Warrants, Provides Corporate Update
Globenewswire· 2025-12-17 12:00
TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, today announced it has exercised its right to call all 500,000 outstanding common share purchase warrants (the “Warrants”) issued ...
e-STORAGE to Deliver 408 MWh Battery Energy Storage System for Vena Energy in South Australia
Prnewswire· 2025-12-17 12:00
KITCHENER, ON, Dec. 17, 2025 /PRNewswire/ -- Canadian Solar Inc. (the "Company" or "Canadian Solar") (NASDAQ: CSIQ) today announced that e-STORAGE, part of the Company's majority-owned subsidiary CSI Solar Co., Ltd. ("CSI Solar"), will deliver 408 MWh AC Battery Energy Storage System (BESS) to Vena Energy for its Tailem Bend 3 project in South Australia. Working alongside Vena Energy and Balance of Plant partner Consolidated Power Projects Australia Pty Ltd (CPP), e-STORAGE will deliver the 204 MW / 408 MW ...
Department of Energy Mandates Centralia Unit 2 Remain Available for Operation for 90 Days
Globenewswire· 2025-12-17 12:00
CALGARY, Alberta, Dec. 17, 2025 (GLOBE NEWSWIRE) -- TransAlta Corporation (TransAlta or the Company) (TSX: TA) (NYSE: TAC) confirms that its subsidiary, TransAlta Centralia Generation LLC, has received an order (the Order) from the United States Department of Energy. The Order mandates that Centralia Unit 2 in Washington State remain available for operation, for a period of 90 days, until March 16, 2026. TransAlta is currently evaluating the Order and will work with the state and federal governments in rela ...
Simply Good Foods to Report First Quarter Fiscal Year 2026 Financial Results on Thursday, January 8, 2026
Globenewswire· 2025-12-17 12:00
DENVER, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The Simply Good Foods Company (NASDAQ: SMPL) (“Simply Good Foods” or the “Company”), a leader in the Nutritional Snacking category, today announced it will report financial results for the first quarter of Fiscal Year 2026 on Thursday, January 8, 2026. A press release will be issued that morning, followed by a live conference call beginning at 6:30 a.m. Mountain Time (8:30 a.m. Eastern Time). Participating on the call will be Geoff Tanner, President and Chief Execut ...
DEFSEC Technologies Announces CAD$2.1 Million Registered Direct Offering
TMX Newsfile· 2025-12-17 12:00
Ottawa, Ontario--(Newsfile Corp. - December 17, 2025) - DEFSEC Technologies Inc. (TSXV: DFSC) (TSXV: DFSC.WT.U) (NASDAQ: DFSC) (NASDAQ: DFSCW) ("DEFSEC" or the "Company"), today announced that it has entered into definitive agreements for the purchase and sale of 566,040 common shares at a purchase price of CAD$3.64 (US$2.65) per common share in a registered direct offering. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 566,040 common shares at an exercis ...
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
Accessnewswire· 2025-12-17 12:00
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p.m. ...
Why Warner Bros. Discovery's board says shareholders should reject Paramount's bid and go with Netflix
Business Insider· 2025-12-17 12:00
Core Viewpoint - Warner Bros. Discovery (WBD) has rejected Paramount Skydance's cash offer of $30 per share, citing it as inadequate and risky compared to Netflix's cash-and-stock proposal of $27.75 per share, which is deemed to provide superior value for shareholders [1][2]. Summary by Sections Offer Comparison - Paramount's bid aims to acquire all of WBD, including its cable channels, while Netflix's offer focuses on WBD's studio, HBO, and HBO Max [2]. - WBD's board has unanimously recommended that shareholders reject Paramount's offer in favor of the Netflix merger [12][13]. Concerns with Paramount's Offer - WBD's board highlighted that Paramount's proposal does not adequately address key concerns, particularly regarding its financing structure, which relies on an "unknown and opaque revocable trust" rather than a solid commitment from the Ellison family [3][16]. - The board emphasized that the financing commitment from Paramount is not as secure as that from Netflix, which is backed by a public company with a market cap exceeding $400 billion [19][20]. Financial Implications - The Netflix merger agreement offers WBD shareholders $23.25 in cash and $4.50 in Netflix stock, along with potential future upside from Discovery Global's separation from WBD [15]. - Accepting Paramount's offer could incur significant costs for WBD, including a $2.8 billion termination fee to Netflix and approximately $1.5 billion in financing costs, totaling around $4.3 billion, or $1.66 per share for WBD shareholders [27]. Regulatory Considerations - WBD's board does not believe there is a material difference in regulatory risk between the two proposals, despite Paramount's claims of easier regulatory approval [7][24]. - Netflix has agreed to a record-setting regulatory termination cash fee of $5.8 billion, which is higher than Paramount's $5 billion break fee [24]. Strategic Review Process - The board conducted a thorough review of strategic alternatives, engaging extensively with all parties, including Paramount, over nearly three months [22]. - Despite multiple opportunities for Paramount to present a superior proposal, it failed to do so, leading to the board's continued support for the Netflix merger [23].
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
Globenewswire· 2025-12-17 12:00
Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC. NXP900, an oral small molecule drug candidate, is a potent inhibitor of the SRC and YES1kinases. The brand name for Osi ...
ONAR Holding Newly Acquired ‘JUICE' Marketing Team, Achieves Record Black Friday Results on All Metrics, Exceeds Volume Targets By 300%+
Globenewswire· 2025-12-17 12:00
Miami, FL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- ONAR Holding Corporation (OTCQB: ONAR) (“ONAR” or the “Company”), an AI-powered marketing platform that acquires and scales specialist agencies, is proud to announce a series of exceptional performance milestones achieved by its recently acquired performance marketing agency, JUICE. Following the acquisition of JUICE earlier this year, the agency’s execution during the critical Black Friday/Cyber Monday (BFCM) period has demonstrated the immediate value and scala ...
NOG Provides Post-Transaction Hedge Profile Update
Businesswire· 2025-12-17 12:00
MINNEAPOLIS--(BUSINESS WIRE)--Northern Oil and Gas, Inc. (NYSE: NOG) (the "Company†or "NOG†) today provided an update on the Company's hedge profile after its recently announced Ohio Utica joint acquisition. HEDGING UPDATE The Company continues to execute its policy of protecting its capital program by periodically entering into financial derivative instruments with counterparties to lock in future commodity prices on a portion of its expected production. NOG has added substantial gas hedges s. ...